AI-driven adaptive therapy device receives 510(k) clearanceMarch 25, 2020
Varian has received FDA 510(k) clearance for its Ethos therapy, an adaptive intelligence solution.
Ethos therapy is an artificial intelligence (AI)-driven holistic solution designed to deliver an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery.
It provides the ability to alter the patient’s treatment based on the patient’s anatomy and position at the time of treatment. The goal is to better target the tumour, reduce dose to healthy tissue, and potentially improve overall outcomes.
The streamlined workflow of Ethos therapy is enabled by its AI-driven planning and contouring capabilities. The physician defines their clinical intent from pre-defined templates and the initial treatment plan is generated based on the physician’s clinical objectives. The treatment is adapted in response to changes in the patient’s anatomy and the tumour’s shape and position, at the time of treatment.
Ethos therapy offers the use of multimodality images (MR, PET, CT) and daily iterative CBCT images at the console.